Survival – Talk Bio

Corcept Highlights Survival Benefit Despite ALS Trial’s Missed Primary Endpoint

3 days ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Benefit, Corcept, DAZALS trial, dazucorilant, Phase 2 Clinical Trials, SURVEY.ALSFRSR, Survival

Corcept Therapeutics; dazucorilant; ALS; amyotrophic lateral sclerosis; DAZALS trial; survival benefit; phase 2 study; ALSFRS-R; ENCALS 2025

Actuate Therapeutics’ Pancreatic Cancer Drug Elraglusib Shows Survival Benefit in Phase 2 Study

5 days ago talkbio0Tagged 130-nm albumin-bound paclitaxel, Actuate, ASCO, Elraglusib, gemcitabine, Metastatic Pancreatic Ductal Adenocarcinoma, Midline (qualifier value), Pancreatic carcinoma, Survival

Actuate Therapeutics; Elraglusib; Pancreatic cancer; Phase 2 trial; Median overall survival; Gemcitabine; Nab-paclitaxel; Metastatic pancreatic ductal adenocarcinoma; Survival benefit; ASCO 2025

AstraZenecas Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails

1 month ago talkbio0Tagged ADT, androgen-deprivation therapy, AstraZeneca, CAPItello-280, capivasertib, Clinical Trials, Discontinuation (procedure), docetaxel, Failure (biologic function), Inhibitor, Metastatic castration-resistant prostate cancer, oncology setback, Phase 3 Clinical Trials, Progression-Free Survival, Proto-Oncogene Proteins c-akt, Radiographic, Survival, Truqap

Truqap, capivasertib, AstraZeneca, Phase III trial failure, CAPItello-280, metastatic castration-resistant prostate cancer (mCRPC), AKT inhibitor, docetaxel, androgen-deprivation therapy (ADT), oncology setback, clinical trial discontinuation, radiographic progression-free survival, overall survival

Navigating the Biotech Winter: Strategies for Survival and Growth Amid Ongoing Industry Downturn

2 months ago talkbio0Tagged Acquisitions, adaptation, Artificial Intelligence, biotech downturn, growth opportunities, innovation, Landscapes, layoff, Precision Medicine, regulatory, strategic, Survival, trends qualifier

biotech downturn, layoff trends, funding challenges, strategic adaptation, innovation, mergers & acquisitions, workforce planning, precision medicine, artificial intelligence, regulatory landscape, survival strategies, growth opportunities